A  Phase IV Study of the Safety and Efficacy of CinnoPar(®) in Iranian Patients with Osteoporosis

The safety of teriparatide has been studied in various phase III and phase IV trials. However, a postmarketing study of the biosimilar of teriparatide, CinnoPar(®), has not been conducted on Iranian patients. This was a phase IV study conducted on osteoporotic patients who received an Iranian teripa...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamshidi, Ahmadreza, Gharibdoost, Farhad, Sedighi, Sima, Hajiabbasi, Asghar, Salari, Amir-Hossein, Khabbazi, Alireza, Mottaghi, Peyman, Tahammoli Roudsari, Ahmad, Aghaei, Mehrdad, Shenavar Masooleh, Irandokht, Sabzvari, Araz, Anjidani, Nassim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184341/
https://www.ncbi.nlm.nih.gov/pubmed/34194720
http://dx.doi.org/10.1155/2021/7584308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184341/
https://www.ncbi.nlm.nih.gov/pubmed/34194720
http://dx.doi.org/10.1155/2021/7584308

Ejemplares similares